The case for informative phase 2 trials in osteosarcoma.
暂无分享,去创建一个
[1] D. Hawkins,et al. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Blay,et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[3] R. Goldsby,et al. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group , 2016, Pediatric blood & cancer.
[4] M. Sydes,et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] K. S. Hall,et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] R. Goldsby,et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. , 2013, European journal of cancer.
[7] J. Healey,et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma , 2011, Cancer.
[8] L. Mirabello,et al. Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.
[9] Paul A Meyers,et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.